Mobile website
Archive > Volume 29 Issue 9 > 2022,29(9):822-827. DOI:10.3872/j.issn.1007-385X.2022.09.006 Prev Next
Clinical Research
Expression characteristics and clinical significance of HHLA2 and its receptor TMIGD2 in ovarian cancer tissues
- Article
- Figures
- Metrics
- Preview PDF
- Reference
- Related
- Cited by
- Materials
Abstract:
Objective: To investigate the expression of human endogenous retrovirus-H long terminal repeat-associating protein 2 (HHLA2) and its receptor TMIGD2 (transmembrane and immunoglobulin domain containing 2) in ovarian cancer tissues and analyze the relationship between their expressions and the clinicopathological characteristics and prognosis of ovarian cancer patients.Methods: The expressions of HHLA2 and its receptor TMIGD2 were detected respectively by immunohistochemistry in a tissue microarray (TMA) containing 154 ovarian cancer tissues. The correlation between the expressions and the clinicopathological characteristics of the patients and the impact on prognosis were analyzed. Results: The expression of HHLA2 was associated with the pathological type of ovarian cancer (P<0.05). Kaplan-Merier survival analysis revealed that the high expression of HHLA2 and TMIGD2 was significantly correlated with poor OS in type Ⅰovarian cancer (P<0.05, P<0.01). Univariate Cox proportional hazard model indicated that type Ⅱ, FIGO stage Ⅲ and Ⅳ, lymphatic metastasis and distant metastasis were significantly associated with worse prognosis. Multivariate Cox proportional hazard model showed that TMIGD2 high expression, FIGO stage Ⅲ and Ⅳ, lymphatic metastasis, positive lymphatic metastasis may be independent influencing factors for poor prognosis of ovarian cancer patients and HHLA2 had significant positive correlation with TMIGD2 expression (r=0.603, P<0.01). Conclusion: HHLA2 and its receptor TMIGD2, which are highly expressed in ovarian cancer tissues and significantly correlated with the prognosis of patients, are expected to be prognostic indicators for ovarian cancer patients.
Keywords:
Project Supported:
Clc Number:
